Companies · Biotech
San Francisco · CA, USA · Biotech · founded 2025 · https://b12-labs.com/
Diligence memoA one-page analyst read on b12 Labs — recommendation, valuation, rhythm, risks.→b12 Labs: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
b12 Labs is one of 233 Biotech companies tracked from San Francisco, CA, USA, on record since 2025. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Chemical Copilot for Pharma and Biotech
b12 is an AI copilot that plans how to create and test new molecules for chemists. We're like a GPS for chemistry, helping pharma companies plan the recipes for new drugs, accelerating early-stage drug discovery from years to months. Andres built the first AI agent that can autonomously think and make molecules in a robotic lab, published in Nature Machine Intelligence (750+ citations), and won the best paper award at the NeurIPS AI for Science conference. Zlatko is a 3x National Chemistry Olympiad champion, competed at IChO level, and medicinal chemist who has worked at Roche and leading lab robotics companies. He has an extensive network of hundreds of chemists across Europe. We are publishing a groundbreaking paper in Nature demonstrating our AI's ability to optimally plan chemical recipes. We run paid pilots with big pharma companies showing that our platform planned a set of experiments that achieved full conversion in a single attempt, eliminating the usual 8-12 iteration cycle.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 67% of sector peers (real $). Modeled value above 67% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
b12 Labs is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| 10x Science | Biotech | — | — | — | same sector |
| 1849 bio | Biotech | — | — | — | same sector |
| 1910 | Biotech | — | — | — | same sector |
| 20n | Biotech | — | — | — | same sector |
| 54Gene, Inc. | Biotech | Series B | $48.3M | $598.4M | same sector |
| Abacus Bioscience Inc. | Biotech | Series A | $4.4M | $46.6M | same sector |
| Abalone Bio | Biotech | — | — | — | same sector |
| Acoustic Wave Cell Therapy, Inc. | Biotech | Series A | $20.5M | $84.9M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| 10x Science The AI-native platform for next-generation protein characterization. | Biotech | — | — | 82% |
| Ditto Biosciences Evolutionary intelligence for autoimmune disease | Biotech | — | — | 81% |
| Nabla Bio We use AI to design antibodies for intractable diseases | Biotech | — | — | 81% |
| Convexia The world's first AI-maximalist pharma company | Biotech | — | — | 80% |
| Synthio Labs Agentic AI platform for Pharma GTM teams | Biotech | — | — | 80% |
| 1910 Multimodal AI Platform for Modality Agnostic Drug Discovery™ | Biotech | — | — | 80% |
| Junction Bioscience AI Hypothesis Engine for Molecular Discovery | Biotech | — | — | 79% |
| Scoop Automating regulatory submissions for life sciences | Biotech | — | — | 79% |
See where b12 Labs sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at b12 Labs, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.